Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 4Recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 71Gastrointestinal 43Head & Neck 30Breast 25Genitourinary 19Other solid neoplasm 17Gynecologic 17Sarcoma 10Lymphoid 9Dermatologic 6Tumor-Agnostic 4CNS 4Plasma cell 3Other hematologic neoplasm 2Endocrine 2NET 1Myeloid 1

Conditions

Glioblastoma 3Lymphoma 1Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × durvalumab × CNS × Clear all
NCT02866747 2026-04-14

STERIMGLI

Institut Claudius Regaud

Phase 1/2 Completed
108 enrolled
CNS

Glioblastoma

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

Children's Hospital Los Angeles

Phase 1 Completed
15 enrolled
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT02336165 2022-10-12

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Ludwig Institute for Cancer Research

Phase 2 Completed
159 enrolled 23 charts
CNS

Glioblastoma

NCT02794883 2022-04-18

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Northwestern University

Phase 2 Completed
36 enrolled 13 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡